Journal
CHEMMEDCHEM
Volume 13, Issue 19, Pages 2104-2118Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201800512
Keywords
antiprotozoal agents; Chagas disease; drug discovery; nitroheterocycles; Trypanosoma cruzi
Categories
Funding
- Spanish Ministry of Economy, Industry and Competitiveness (MINEICO) [SAF2015-66690-R, CSD2010-00065]
- FONDECYT (Chile) [11150559]
- Junta de Andalucia [P11-CTS-07187]
- FPU Grant from the Ministry of Education of Spain [FPU14/01537]
- Junta de Andalucia
Ask authors/readers for more resources
Chagas disease, a neglected tropical disease caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially life-threatening illness that affects 5-8 million people in Latin America, and more than 10 million people worldwide. It is characterized by an acute phase, which is partly resolved by the immune system, but then develops as a chronic disease without an effective treatment. There is an urgent need for new antiprotozoal agents, as the current standard therapeutic options based on benznidazole and nifurtimox are characterized by limited efficacy, toxicity, and frequent failures in treatment. In vitro and in vivo assays were used to identify some new low-cost 5-nitroindazoles as a potential antichagasic therapeutic alternative. Compound 16 (3-benzyloxy-5-nitro-1-vinyl-1H-indazole) showed improved efficiency and lower toxicity than benznidazole in both in vitro and in vivo experiments, and its trypanocidal activity seems to be related to its effect at the mitochondrial level. Therefore, compound 16 is a promising candidate for the development of a new anti-Chagas agent, and further preclinical evaluation should be considered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available